Biocryst Pharmaceuticals (BCRX) Return on Capital Employed (2011 - 2026)
Biocryst Pharmaceuticals' (BCRX) quarterly Return on Capital Employed came in at 129.78% in Q1 2026, down 13939.0% YoY from N/an in Q1 2025, and down 208.18% on a QoQ basis from 119.97% in Q4 2025.
Biocryst Pharmaceuticals (BCRX) Return on Capital Employed (2011 - 2026) Analysis & Trends
Biocryst Pharmaceuticals (BCRX) has 16 years of Return on Capital Employed data on file, last reported at 129.78% in Q1 2026.
- Quarterly Return on Capital Employed fell 13939.0% year-over-year to 129.78% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 129.78% (down 13939.0% YoY) and the FY2025 annual result came in at 111.35%, up 11209.0% from the prior year.
- Return on Capital Employed fell to 129.78% in Q1 2026, from 119.97% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 119.97% in Q4 2025 to a low of 129.78% in Q1 2026.
- A 5-year average of 15.42% and a median of 24.64% in 2023 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2025 — Return on Capital Employed surged 12074 bps — and 2026, when it slumped 13939 bps.
- Tracing BCRX's Return on Capital Employed over 5 years: stood at 33.08% in 2022, then grew by 15 bps to 28.03% in 2023, then jumped by 97 bps to 0.77% in 2024, then soared by 15690 bps to 119.97% in 2025, then sank by 208 bps to 129.78% in 2026.
- The last three Return on Capital Employed figures came in at 129.78% (Q1 2026), 119.97% (Q4 2025), and 29.09% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 6.60% |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 17.16% |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 6.07% |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 22.04% |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -0.29% |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 18.67% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 5.52% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Biocryst Pharmaceuticals | 2.46 Bn | 2.11 Bn | 214.41 Mn | -103.49% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -103.49% |
| Mar 31, 2026 | -129.78% |
| Dec 31, 2025 | 119.97% |
| Sep 30, 2025 | 29.09% |
| Jun 30, 2025 | 18.60% |
| Mar 31, 2025 | 9.60% |
| Dec 31, 2024 | -0.77% |
| Sep 30, 2024 | -12.40% |
| Jun 30, 2024 | -17.68% |
| Mar 31, 2024 | -24.10% |
| Dec 31, 2023 | -28.03% |
| Sep 30, 2023 | -24.64% |
| Jun 30, 2023 | -26.48% |
| Mar 31, 2023 | -28.53% |
| Dec 31, 2022 | -33.08% |
| Sep 30, 2022 | -34.07% |
| Jun 30, 2022 | -42.82% |
| Mar 31, 2022 | -36.97% |
| Dec 31, 2021 | -54.98% |
| Sep 30, 2021 | -129.03% |